Search results
The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A Record
Investor's Business Daily· 6 days agoAvidity Biosciences unveiled "impressive" results from a study of its treatment for a rare form of ...
Pfizer 'can't rule out' layoffs in North Carolina after gene therapy flub - Triangle Business...
The Business Journals· 11 hours agoLayoffs could by on the way at Pfizer's massive facility in Sanford after the company's gene therapy...
FDA approves generic Emflaza oral suspension for Duchenne muscular dystrophy
Medical Xpress· 2 days agoThe U.S. Food and Drug Administration has approved the first generic version of Emflaza...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 6 days agoSECTORFOCUS BLOG A second failure of a late-stage trial testing a gene therapy to treat Duchenne ...
Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss
BioPharma Dive via Yahoo Finance· 7 days agoStudy results indicated Avidity’s medicine muted target genes. Elsewhere, Syntis revealed obesity...
Pfizer's gene-therapy trial failure boosts Sarepta's stock
Morningstar· 6 days agoShares of Sarepta Therapeutics Inc. (SRPT) gained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial. Pfizer Inc. said late Wednesday that ...
$10,000 for 10 years: Chesterfield-based organization helping those with neuromuscular disorders
WRIC 8 News Richmond· 6 days agoFor ten years, the Colorado Fund for Muscular Dystrophy (CMFD) has been working to improve the lives...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with...
Morningstar· 6 days agoThe primary endpoint in the final analysis was assessed by change in the North Star Ambulatory...
Bill headed to Pritzker's desk will screen babies for Duchenne muscular dystrophy
Chicago Sun-Times· 4 days agoMy wife and I could’ve never guessed a blood test would send our world crashing into a fatal...
Sarepta’s stock gains after Pfizer’s Duchenne trial failure - Boston Business Journal
The Business Journals· 6 days agoSarepta Therapeutics, a Cambridge drugmaker known for its Duchenne muscular dystrophy treatments,...